Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere et al' by Buckley

Nicola Potere^{1

2}, Marcello Di Nisio^{3

4}, Donatella Cibelli⁵, Rosa Scurti⁶, Antonella Frattari⁷, Ettore Porreca¹, Antonio Abbate², Giustino Parruti⁸

Affiliations

¹ Department of Medical, Oral and Biotechnological Sciences, Università degli Studi Gabriele d'Annunzio, Chieti, Italy.
² VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.
³ Department of Medicine and Ageing Sciences, Università degli Studi Gabriele d'Annunzio, Chieti-Pescara, Italy.
⁴ Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
⁵ Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy.
⁶ Geriatric Medicine Unit, Pescara General Hospital, Pescara, Italy.
⁷ Intensive Care Unit, Pescara General Hospital, Pescara, Italy.
⁸ Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy parrutig@gmail.com.

Comment

Nicola Potere et al. Ann Rheum Dis. 2022 Oct.

. 2022 Oct;81(10):e195.

doi: 10.1136/annrheumdis-2020-218715. Epub 2020 Sep 1.

Nicola Potere^{1

2}, Marcello Di Nisio^{3

4}, Donatella Cibelli⁵, Rosa Scurti⁶, Antonella Frattari⁷, Ettore Porreca¹, Antonio Abbate², Giustino Parruti⁸

¹ Department of Medical, Oral and Biotechnological Sciences, Università degli Studi Gabriele d'Annunzio, Chieti, Italy.
² VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.
³ Department of Medicine and Ageing Sciences, Università degli Studi Gabriele d'Annunzio, Chieti-Pescara, Italy.
⁴ Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
⁵ Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy.
⁶ Geriatric Medicine Unit, Pescara General Hospital, Pescara, Italy.
⁷ Intensive Care Unit, Pescara General Hospital, Pescara, Italy.
⁸ Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy parrutig@gmail.com.

No abstract available

Keywords: biological therapy; cytokines; glucocorticoids; inflammation.

Conflict of interest statement

Competing interests: None declared.

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.
Potere N, Di Nisio M, Cibelli D, Scurti R, Frattari A, Porreca E, Abbate A, Parruti G. Potere N, et al. Ann Rheum Dis. 2021 Feb;80(2):1-2. doi: 10.1136/annrheumdis-2020-218243. Epub 2020 Jul 9. Ann Rheum Dis. 2021. PMID: 32647027 No abstract available.
Correspondence on 'Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere et al.
Buckley L. Buckley L. Ann Rheum Dis. 2022 Oct;81(10):e194. doi: 10.1136/annrheumdis-2020-218693. Epub 2020 Sep 1. Ann Rheum Dis. 2022. PMID: 32873553 No abstract available.